Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Anti-PD-L1 Immunotherapy Plus Abraxane Significantly Reduced Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer

Celgene Corporation today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival.

Read More »

AstraZeneca wins speedy approvals for cancer drugs in Japan

AstraZeneca won rapid regulatory approval for new uses of two of the company’s important cancer drugs in Japan.

Read More »

Roche ‘highly encouraged’ by Tecentriq results in breast cancer

Roche said a clinical trial showed the Swiss drugmaker’s immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

Read More »

Puma Biotech gets EU panel nod for breast cancer drug

Puma Biotechnology Inc. won a key recommendation from a European Medicines Agency panel on the company’s lead breast cancer drug, five months after the regulator recommended against approving it.

Read More »

Breast cancer drug combo falls short of survival goal

A combination of Pfizer’s breast cancer medicine Ibrance and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.

Read More »

FDA, EMA Accept Regulatory Filings for Talazoparib

The U.S. Food and Drug Administration and the European Medicines Agency accepted for regulatory review Pfizer’s approval applications for talazoparib.

Read More »

Breast cancer screening failure may have shortened 270 lives in England

As many as 270 women in England may have died prematurely of breast cancer because of an IT failure that led to 450,000 patients missing out on routine screening appointments.


Read More »

Stock Dives as Celldex Cuts 20% of Staff After Phase II Breast Cancer Failure

Celldex Therapeutics reported that the company’s Phase IIb trial of glembatumumab vedotin (glemba) failed in a trial of metastatic triple-negative breast cancer. Celldex has filed with the U.S. Securities and Exchange Commission that it’s cutting about 20 percent of staff.

Read More »

FDA declines to approve Pfizer biosimilar

Pfizer Inc. said on Monday U.S. regulators declined to approve the company’s biosimilar of Roche’s blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.

Read More »

Eli Lilly Shows Off More Verzenio Data at AACR

Eli Lilly unveiled final data from the MONARCH 3 study that helped the drug garner FDA approval in February 2018 for the treatment of some breast cancer patients.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom